• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets

    9/30/25 8:00:00 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care
    Get the next $TRIL alert in real time by email

    NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in innovative and first-mover exchange-traded funds, today announced the launch of the Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL), the first ETF designed to give investors exposure to the exclusive group of companies and crypto assets with market capitalizations above $1 trillion (the "Trillion Dollar Assets").

    TRIL seeks to track the performance, before fees and expenses, of the BITA Trillion Dollar Club Index, which includes U.S. exchange-listed companies and U.S.-listed crypto ETFs tied to assets valued at $1 trillion or greater. As of September 15, 2025, the trillion-dollar club included Tesla, Alphabet, NVIDIA, Microsoft, Meta Platforms, iShares Bitcoin Trust ETF, Broadcom, Apple, Amazon, and Berkshire Hathaway. These represent the global market leaders driving the AI, cloud, semiconductor, electric vehicle, and digital asset revolutions.

    "The Magnificent 7 is a thing of the past. We believe assets over $1 trillion will become the primary proxy for index investing, fueled by the AI revolution and the evolution of Bitcoin. Crossing the trillion-dollar threshold is more than a milestone — it's a declaration of global dominance," said Sylvia Jablonski, CIO of Defiance ETFs.

    About Defiance

    Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Its first-mover leveraged single-stock and crypto-linked ETFs empower investors to take amplified positions in high-growth themes, providing precise leverage exposure without the need for a margin account.

    Important Disclosures

    The Fund's investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read the prospectus and/or summary prospectus carefully before investing. Hard copies can be requested by calling 833.333.9383

    Defiance ETFs LLC is the ETF sponsor. The Fund's investment adviser is Tidal Investments, LLC ("Tidal" or the "Adviser")

    Investing involves risk. Principal loss is possible. As an ETF, the Fund may trade at a premium or discount to NAV. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the Fund.

    Equity Market Risk. Equity securities may experience sudden, unpredictable drops in value or long periods of decline in value due to factors that affect securities markets generally or specific issuers, industries, or sectors.

    Crypto Assets and Bitcoin Risk. The Fund does not invest directly in crypto assets but may gain indirect exposure to bitcoin through ETFs. Bitcoin and other crypto assets are highly volatile, subject to fraud, theft, manipulation, forks, regulatory changes, and market disruptions, which can adversely affect the Fund.

    Derivatives Risk. The Fund may use swaps and other derivatives to gain exposure to Index components. Derivatives can be more volatile than other investments and may magnify losses.

    Sector and Industry Risk. The Fund may concentrate in certain sectors, particularly information technology and semiconductors, making it sensitive to sector-specific developments.

    Large-Capitalization Investing. Securities of large-capitalization companies may be relatively mature and slower-growing than smaller companies, and may be less able to adapt quickly to competitive challenges.

    Crypto Asset Markets Risk: The crypto asset market, particularly bitcoin, has experienced considerable volatility, leading to market disruptions and erosion of confidence among market participants. This instability and the resultant negative publicity could adversely affect the Fund's reputation and trading prices. Ongoing market turbulence could significantly impact the value of the Fund's share. Inclusion of crypto assets in the Index may result in higher volatility for the Fund than if crypto assets were not included in the Index. In addition, there may be periods when crypto assets comprise a significant portion of the Fund, which may lead to increased risk. Non-Diversification Risk. Because the Fund is "non-diversified," it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund. As a result, a decline in the value of an investment in a single issuer or a smaller number of issuers could cause the Fund's overall value to decline to a greater degree than if the Fund held a more diversified portfolio.

    New Fund Risk. The Fund is recently organized with no operating history, so investors have no track record on which to base decisions.

    Market Capitalization: A company's market capitalization is determined based on the number of shares outstanding of such company multiplied by such company's per share price.

    The BITA Trillion Dollar Club Index is a financial index, owned and administered by BITA GmbH, that tracks the performance of publicly traded U.S. companies with a market capitalization of $1 trillion or greater. An index is unmanaged and it is not possible to invest directly in an index.

    The Magnificent 7 refers to seven leading U.S. technology companies—Apple, Microsoft, Alphabet, Amazon, NVIDIA, Tesla, and Meta—that have driven a significant share of stock market performance in recent years.

    Holdings are subject to change. For the funds current holdings please visit www.defianceetfs.com/tril

    Diversification does not ensure a profit nor protect against loss in a declining market. Brokerage commissions may be charged on trades.

    TRIL is distributed by Foreside Fund Services, LLC

    Contact information

    David Hanono

    [email protected]

    833.333.9383

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1d8efd93-8633-4923-975c-afac7e91afb9



    Get the next $TRIL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRIL

    DatePrice TargetRatingAnalyst
    11/17/2021Buy → Hold
    The Benchmark Company
    11/17/2021Buy → Hold
    Benchmark
    8/24/2021$21.00 → $18.50Buy → Hold
    Craig-Hallum
    8/24/2021Market Outperform → Market Perform
    JMP Securities
    8/23/2021$22.00 → $18.50Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $TRIL
    SEC Filings

    View All

    SEC Form 15-12B filed by Trillium Therapeutics Inc.

    15-12B - Trillium Therapeutics Inc. (0001616212) (Filer)

    11/29/21 6:31:18 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Trillium Therapeutics Inc.

    EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)

    11/22/21 12:15:09 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Trillium Therapeutics Inc.

    EFFECT - Trillium Therapeutics Inc. (0001616212) (Filer)

    11/22/21 12:15:09 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    $TRIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Trillium Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Trillium Therapeutics from Buy to Hold

    11/17/21 7:54:15 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Trillium Therapeutics downgraded by Benchmark

    Benchmark downgraded Trillium Therapeutics from Buy to Hold

    11/17/21 6:38:15 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Trillium Therapeutics downgraded by Craig-Hallum with a new price target

    Craig-Hallum downgraded Trillium Therapeutics from Buy to Hold and set a new price target of $18.50 from $21.00 previously

    8/24/21 8:29:10 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    $TRIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets

    NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in innovative and first-mover exchange-traded funds, today announced the launch of the Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL), the first ETF designed to give investors exposure to the exclusive group of companies and crypto assets with market capitalizations above $1 trillion (the "Trillion Dollar Assets"). TRIL seeks to track the performance, before fees and expenses, of the BITA Trillion Dollar Club Index, which includes U.S. exchange-listed companies and U.S.-listed crypto ETFs tied to assets valued at $1 trillion or greater. As of September 15, 2025, the trillion-dollar club included Tesla, Alphabet,

    9/30/25 8:00:00 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

    Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini

    6/17/22 7:00:00 AM ET
    $DMAC
    $ONCY
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Trillium Therapeutics Receives Final Court Order Approving Arrangement

    CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with PF Argentum ULC ("PF Argentum"), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE:PFE) ("Pfizer"). Pursuant to the Arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium other than Trillium securities owned by Pfizer and its affiliates

    10/28/21 5:00:00 PM ET
    $PFE
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    $TRIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company

    4 - Trillium Therapeutics Inc. (0001616212) (Issuer)

    11/19/21 3:34:15 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Pucci Paolo

    4 - Trillium Therapeutics Inc. (0001616212) (Issuer)

    11/19/21 1:33:49 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Myers Scott Dunseth

    4 - Trillium Therapeutics Inc. (0001616212) (Issuer)

    11/19/21 1:33:02 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    $TRIL
    Leadership Updates

    Live Leadership Updates

    View All

    Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

    Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini

    6/17/22 7:00:00 AM ET
    $DMAC
    $ONCY
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

    CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately. "We are excited to welcome Dr. Mackey to our board of directors," said Paolo Pucci, Lead Director of Trillium.  "Her significant executive experience and expertise leading research and development organizations will be invaluable as Trillium advances its two lead product candidates into a Phase 1b/2 program." Dr. Mackey has more t

    6/30/21 7:00:00 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

    MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate. Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio. Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new

    1/7/21 8:00:00 AM ET
    $TRIL
    $PHAT
    $RCKT
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $TRIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Trillium Therapeutics Inc. (Amendment)

    SC 13D/A - Trillium Therapeutics Inc. (0001616212) (Subject)

    11/19/21 6:44:02 AM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Trillium Therapeutics Inc. (Amendment)

    SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)

    4/7/21 4:32:50 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Trillium Therapeutics Inc. (0001616212) (Subject)

    2/16/21 5:17:54 PM ET
    $TRIL
    Major Pharmaceuticals
    Health Care

    $TRIL
    Financials

    Live finance-specific insights

    View All

    Pfizer to Acquire Trillium Therapeutics Inc.

    Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives Pfizer Inc. (NYSE:PFE) and Trillium Therapeutics Inc. (TSX:TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire al

    8/23/21 6:45:00 AM ET
    $PFE
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals